Clinical Trial

Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

Study acronym: TILT-2024
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to see if the clinical use of Tirzepatide in patients with lipodystrophy (a rare disorder associated with abnormal loss of the body's fat tissue) may lead to improved diabetes mellitus control and lowering of participant's triglycerides through the reduction of caloric intake. Study Hypothesis: \- The clinical use of Tirzepatide in patients with lipodystrophy may lead to favorable outcomes through the reduction of caloric intake.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-21.
Status change: Not Yet Recruiting → Recruiting 2025-09-08
Trial Details
NCT Number NCT07091734
Lead Sponsor University of Michigan
Conditions Lipodystrophy, Partial
Enrollment 32 participants
Start Date 2025-09-08
Primary Completion 2029-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2025-09-09